{
    "2018-05-31": [
        [
            {
                "time": "",
                "original_text": "2018年最吸睛的跨国药企高管变动",
                "features": {
                    "keywords": [
                        "跨国药企",
                        "高管变动"
                    ],
                    "sentiment_score": -0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[强烈推荐评级]复星医药(600196)公司事件点评：CD20靶点利妥昔单抗类似药III期临床完成 上市在即",
                "features": {
                    "keywords": [
                        "复星医药",
                        "CD20靶点",
                        "利妥昔单抗",
                        "III期临床",
                        "上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]医药生物行业事件点评：国家医疗保障局成立 结构化行情长期持续",
                "features": {
                    "keywords": [
                        "国家医疗保障局",
                        "医药生物",
                        "结构化行情"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "盘后研报精选：关注这三只累积涨幅较大个股",
                "features": {
                    "keywords": [
                        "盘后研报",
                        "累积涨幅",
                        "个股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[增持评级]医药生物行业点评：金斯瑞CAR-T临床美国获批 中国细胞疗法又一里程碑",
                "features": {
                    "keywords": [
                        "金斯瑞",
                        "CAR-T",
                        "临床",
                        "美国",
                        "细胞疗法"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【平安重点】行业专题报告*生物医药*PD-1/PD-L1元年，领先公司：抢先上市+联合用药*强于大市",
                "features": {
                    "keywords": [
                        "生物医药",
                        "PD-1",
                        "PD-L1",
                        "抢先上市",
                        "联合用药"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "午评：恒指涨0.75%企稳30000点 “三桶油”集体走高",
                "features": {
                    "keywords": [
                        "恒指",
                        "三桶油",
                        "涨"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "能源"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药股泡沫破了？",
                "features": {
                    "keywords": [
                        "医药股",
                        "泡沫破了"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "5月31日券商晨会研报汇编",
                "features": {
                    "keywords": [
                        "券商晨会",
                        "研报汇编"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医疗股大跌原因找到了，可以低吸这些龙头！",
                "features": {
                    "keywords": [
                        "医疗股",
                        "大跌",
                        "低吸",
                        "龙头"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【山证医药】医药行业19年中期策略：科创助力产业升级，生物医药迎黄金发展期",
                "features": {
                    "keywords": [
                        "山证医药",
                        "产业升级",
                        "生物医药",
                        "黄金发展期"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "奇瑞混改疑云：与姚振华“争抢”奇瑞 郭广昌入局造车第一站？",
                "features": {
                    "keywords": [
                        "奇瑞",
                        "混改",
                        "姚振华",
                        "郭广昌",
                        "造车"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "汽车"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}